Harvard Apparatus Regenerative Technology, Inc.

HRGN is a bioengineering company that is developing next-generation esophageal implants.

General Information
Company Name
Harvard Apparatus Regenerative Technology, Inc.
Founded Year
2012
Location (Offices)
Holliston, United States +1
Founders / Decision Makers
David Green - Founder. Currently Chairman and CEO. William Fodor, Ph.D. Fodor - Chief Scientific Officer Joseph Damasio Jr., Active CPA Damasio - Chief Financial Officer
Number of Employees
13
Industries
Biotechnology, Health Care, Medical Devices
Funding Stage
Post Ipo Equity
Social Media

Harvard Apparatus Regenerative Technology, Inc. - Company Profile

Harvard Apparatus Regenerative Technology, Inc. (HRGN) is a bioengineering company founded in 2012. Their slogan, "HRGN is a bioengineering company that is developing next-generation esophageal implants." succinctly captures their mission. The company is based in the United States and operates within the Biotechnology and Health Care sectors. Their focus is on developing organ replacement therapies using cellular scaffolds and tissue engineering to restore organ function. The most recent investment in HRGN was a $6.00M Post-IPO Equity investment on 31 March 2023. This investment indicates continued confidence in the company's innovative approach to regenerative medicine. As the company progresses through its clinical stage, the level of interest from investors may further amplify, positioning HRGN for impactful growth and advancements in the field of regenerative medicine.

Taxonomy: bioengineering, esophageal implants, organ replacement therapies, cellular scaffolds, tissue engineering, regenerative medicine, stem cells, organ regeneration, esophageal replacement, cancer treatment, trauma recovery, birth defects, clinical stage, medical implants

Funding Rounds & Investors of Harvard Apparatus Regenerative Technology, Inc. (11)

View All
Funding Stage Amount No. Investors Investors Date
Post-IPO Equity $1.50M - 15 Apr 2024
Post-IPO Equity $6.00M - 31 Mar 2023
Post-IPO Equity $5.10M - 13 May 2022
Post-IPO Equity $2.60M - 08 Sep 2021
Post-IPO Equity $500.00K - 18 Aug 2020

View All 11 Funding Rounds

Latest News of Harvard Apparatus Regenerative Technology, Inc.

View All

No recent news or press coverage available for Harvard Apparatus Regenerative Technology, Inc..

Similar Companies to Harvard Apparatus Regenerative Technology, Inc.

View All
XVIVO Abdominal - Similar company to Harvard Apparatus Regenerative Technology, Inc.
XVIVO Abdominal We believe in an extended life of organs. Nobody should die waiting for a new organ.
Mississippi Organ Recovery Agency - Similar company to Harvard Apparatus Regenerative Technology, Inc.
Mississippi Organ Recovery Agency The mission of our not-for-profit organization is to save & improve lives through the gift of organ and tissue donation.
Clinical Consulting Associates, Inc. - Similar company to Harvard Apparatus Regenerative Technology, Inc.
Clinical Consulting Associates, Inc. Professional and flexible staffing and consulting solutions for OPOs and Tissue Banks
vitOrgan Arzneimittel GmbH - Similar company to Harvard Apparatus Regenerative Technology, Inc.
vitOrgan Arzneimittel GmbH Weck die Kraft der Zellen Die Brücke zwischen Schulmedizin und Naturheilkunde
Advanced Life Solutions - Similar company to Harvard Apparatus Regenerative Technology, Inc.
Advanced Life Solutions At ALS we ensure that every organ is an opportunity for another patient to live. With ALS expect more.